In a groundbreaking study that promises to reshape our understanding of tick-borne encephalitis virus (TBEV) neuropathogenesis, scientists have identified a pivotal host receptor that facilitates viral entry into human cells. TBEV is recognized as a formidable neurotropic pathogen responsible for tick-borne encephalitis (TBE), a severe neurological disease characterized by viral infiltration of the central nervous system and ensuing neuroinflammation, often leading to debilitating outcomes or mortality. Despite its significant public health impact across Eurasia, the precise mechanisms by which TBEV gains entry into host cells have remained elusive, hampering efforts to develop targeted antiviral therapies.
This latest research leverages the cutting-edge genome-scale CRISPR–Cas9 screening technology to systematically interrogate host genes potentially involved in TBEV infection. Among an expansive array of candidates, the low-density lipoprotein receptor-related protein 8 (LRP8) surfaced as a critical mediator of viral attachment and internalization. LRP8 is well-known for its physiological roles in neuronal signaling, acting as a receptor for key ligands including apolipoprotein E and reelin, and its high expression within brain tissues aligned with the virus’s neurotropic profile.
Detailed mechanistic studies demonstrated that LRP8 directly interacts with the TBEV envelope E glycoprotein, a surface protein essential for virus-host cell fusion and entry. The binding between LRP8 and the TBEV E protein was shown to be the primary molecular event facilitating viral attachment to the host cell surface. This discovery underscores LRP8’s function not merely as a passive marker of susceptibility but as an active participant in the viral life cycle. Importantly, when LRP8 expression was experimentally downregulated in human cell lines, a marked reduction in TBEV infectivity ensued, confirming the receptor’s indispensability in establishing infection.
Conversely, overexpressing LRP8 substantially enhanced viral entry, highlighting a direct relationship between receptor abundance and susceptibility. Further functional assays revealed that LRP8 mediates not only viral binding but also the internalization process, where the virus is engulfed into host cells, a critical step preceding genome release and replication. These findings collectively provide robust evidence that LRP8 serves as a bona fide receptor for TBEV, resolving a long-standing question in flavivirology concerning the molecular gateways exploited by this virus.
The translational implications of this discovery are profound. By designing a soluble decoy receptor based on LRP8’s binding domain, researchers effectively neutralized TBEV in vitro, blocking infection across diverse human cell types, including neurons that are the primary targets in TBE pathogenesis. This LRP8-based decoy acted as a molecular lure, sequestering viral particles and preventing them from engaging with cell-surface receptors, thereby halting the infection cycle at its inception.
Strikingly, in vivo experiments furnished compelling evidence that administration of the LRP8 decoy afforded significant protection against lethal TBEV challenge in murine models. This achievement paves the way for novel therapeutic strategies aimed at intercepting the virus before central nervous system invasion occurs. Such approaches could revolutionize treatment paradigms, offering hope against a disease currently limited to supportive care and preventive vaccination.
Beyond immediate clinical applications, this work illuminates broader principles relevant to neurotropic flaviviruses. It emphasizes the intricate interplay between viral envelope proteins and host receptors, and how this dynamic shapes tissue tropism and disease severity. The identification of LRP8 as a receptor also invites exploration into whether related viruses exploit similar mechanisms, fostering cross-disciplinary insights that could accelerate antiviral drug discovery.
The methodology employed—combining high-throughput genetic screening with biochemical and virological validation—represents a powerful framework for dissecting virus-host interactions. This screen captured the complexity of cellular pathways and receptor networks, allowing the pinpointing of LRP8 amongst a multitude of surface molecules, thereby exemplifying the potential of functional genomics in infectious disease research.
Moreover, the neurocentric expression pattern of LRP8 provides an elegant explanation for the selective vulnerability of the brain to TBEV infection. Since virus entry is receptor-dependent, the high density of LRP8 in neuronal cells likely facilitates efficient viral dissemination within central nervous system tissue, exacerbating neuroinflammation and pathology. Therapies targeting LRP8-virus engagement could therefore selectively mitigate brain infection without broad systemic effects.
This discovery also serves as a platform for further studies probing the structural biology of the LRP8-TBEV E protein interaction. High-resolution structural analyses, possibly via cryo-electron microscopy or X-ray crystallography, could elucidate the precise contact points and conformational changes involved, ultimately guiding rational design of inhibitors that block receptor binding.
On a public health scale, understanding the molecular determinants of TBEV entry opens avenues for improved diagnostic tools that detect viral binding intermediates or receptor expression profiles predictive of susceptibility. Such biomarker development could enhance surveillance and risk stratification in endemic regions where tick exposure is common.
In summary, the identification of LRP8 as a functional receptor for TBEV represents a seminal advancement in the field of neurovirology. By elucidating the molecular gateway for viral entry, this work not only deepens comprehension of TBE pathogenesis but also accelerates the path toward effective countermeasures. The dual utility of LRP8 as a biomolecular target for both therapeutic intervention and biomarker discovery holds promise for mitigating the global burden posed by tick-borne encephalitis.
Subject of Research: Tick-borne encephalitis virus (TBEV) host cell entry mechanisms and receptor identification
Article Title: LRP8 is a receptor for tick-borne encephalitis virus
Article References:
Mittler, E., Tse, A.L., Tran, PTH. et al. LRP8 is a receptor for tick-borne encephalitis virus. Nature (2025). https://doi.org/10.1038/s41586-025-09500-2
Image Credits: AI Generated
Tags: antiviral therapy development challengesCRISPR-Cas9 screening technologyhost gene involvement in TBEV infectionLRP8 receptor physiological rolesLRP8 tick-borne encephalitis receptorneuroinflammation and TBEneurotropic pathogens and diseasesTBEV envelope E glycoprotein interactionTBEV neuropathogenesistick-borne encephalitis virusviral attachment and internalization mechanismsviral entry into human cells
